MedTrace Logo

Revision of the EORTC QLQ-BN20 Questionnaire

NCT04689321 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 135

Last updated 2020-12-30

No results posted yet for this study

Summary

Despite the fact that use of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Brain Neoplasm (QLQ-BN20) has tremendously contributed to insight into the health-related quality of life (HRQoL) of brain tumor patients, certain items of the questionnaire have raised issues, and new treatments have been introduced, with different toxicity profiles not covered by the current measure. These observations have led to the recognition that a revision of the QLQ-BN20 is warranted.

The aim of this project is to update the current EORTC QLQ-BN20 questionnaire.

Conditions

  • Glioma
  • Brain Metastases, Adult

Interventions

OTHER

No intervention

This is not an interventional study.

Sponsors & Collaborators

  • Medical Center Haaglanden

    collaborator OTHER

  • Regina Elena Cancer Institute

    collaborator OTHER

  • San Giovanni Addolorata Hospital

    collaborator OTHER

  • NHS Lothian

    collaborator OTHER_GOV

  • University Hospital Regensburg

    collaborator OTHER

  • University Hospital, Bonn

    collaborator OTHER

  • University of Zurich

    collaborator OTHER

  • National Cancer Center, Japan

    collaborator OTHER_GOV

  • King Hussein Cancer Center

    collaborator OTHER

  • Clinical Hospital Center Rijeka

    collaborator OTHER

  • Leeds Cancer Centre at St. James's University Hospital

    collaborator OTHER

  • Leiden University Medical Center

    lead OTHER

Principal Investigators

  • Linda Dirven, PhD · Leiden University Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-19
Primary Completion
2024-01-01
Completion
2024-01-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04689321 on ClinicalTrials.gov